Why the Amlitelimab Setback Isn’t Enough to Sink Sanofi’s Multi-Billion Dollar Engine

insidermonkey.com · 2026-08-10

It was reported on July 24 that Sanofi (NASDAQ:SNY) shares underperformed in European trading following the company’s decision to drop the clinical development of its eczema candidate, amlitelimab, ...

Read the full story at insidermonkey.com →